

Journal of Visualized Experiments

Merkel Cell Polyomavirus Infection and Detection

--Manuscript Draft--

Article Type:	Invited Methods Article - JoVE Produced Video
Manuscript Number:	JoVE58950R2
Full Title:	Merkel Cell Polyomavirus Infection and Detection
Keywords:	Merkel cell polyomavirus, isolation, dermal fibroblasts, infection, collagenase IV, CHIR99021, immunofluorescent staining, fluorescence in situ hybridization, In situ DNA-hybridization chain reaction, transcription, replication
Corresponding Author:	Jianxin You University of Pennsylvania Philadelphia, PA UNITED STATES
Corresponding Author's Institution:	University of Pennsylvania
Corresponding Author E-Mail:	jianyou@pennmedicine.upenn.edu
Order of Authors:	Jianxin You Wei Liu Nathan Krump Christopher B. Buck
Additional Information:	
Question	Response
Please indicate whether this article will be Standard Access or Open Access.	Standard Access (US\$2,400)
Please indicate the city, state/province, and country where this article will be filmed . Please do not use abbreviations.	Philadelphia, PA 19104, USA

TITLE:

Merkel Cell Polyomavirus Infection and Detection

AUTHORS:

Wei Liu^{1*}, Nathan A. Krump^{1*}, Christopher B. Buck², and Jianxin You^{1#}

¹Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

²Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, MD

*These authors contributed equally

Email Address of Co-Authors:

Wei Liu (weiliu2@pennmedicine.upenn.edu)

Nathan A. Krump (nkrump@pennmedicine.upenn.edu)

Christopher B. Buck (buckc@mail.nih.gov)

Corresponding Author:

Jianxin You (jianyou@mail.med.upenn.edu)

KEYWORDS:

Merkel cell polyomavirus, isolation, dermal fibroblasts, infection, collagenase IV, CHIR99021, immunofluorescent staining, fluorescence in situ hybridization, in situ DNA-hybridization chain reaction, transcription, replication

SUMMARY:

Here, we present a protocol to infect primary human dermal fibroblast with MCPyV. The protocol includes isolation of dermal fibroblasts, preparation of MCPyV virions, virus infection, immunofluorescence staining, and fluorescence in situ hybridization. This protocol can be extended for characterizing MCPyV-host interactions and discovering other cell types infectable by MCPyV.

ABSTRACT:

Merkel cell polyomavirus (MCPyV) infection can lead to Merkel cell carcinoma (MCC), a highly aggressive form of skin cancer. Mechanistic studies to fully investigate MCPyV molecular biology and oncogenic mechanisms have been hampered by a lack of adequate cell culture models. Here, we describe a set of protocols for performing and detecting MCPyV infection of primary human skin cells. The protocols describe the isolation of human dermal fibroblasts, preparation of recombinant MCPyV virions, and detection of virus infection by both immunofluorescent (IF) staining and in situ DNA-hybridization chain reaction (HCR), which is a highly sensitive fluorescence in situ hybridization (FISH) approach. The protocols herein can be adapted by interested researchers to identify other cell types or cell lines that support MCPyV infection. The described FISH approach could also be adapted for detecting low levels of viral DNAs present in the infected human skin.

INTRODUCTION:

Merkel cell polyomavirus (MCPyV) is a small, double-stranded DNA virus that has been associated with a rare but aggressive skin cancer, Merkel cell carcinoma (MCC)^{1,2}. The mortality rate of MCC, around 33%, exceeds that of melanoma^{3,4}. MCPyV has a circular genome of ~5 kb^{1,5} bisected by a non-coding regulatory region (NCRR) into early and late coding regions¹. The NCRR contains the viral origin of replication (Ori) and bidirectional promoters for viral transcription^{6,7}. The early region encodes tumor antigen proteins called large T (LT), small T (sT), 57kT, alternative LT ORF (ALTO), as well as an autoregulatory miRNA^{1,8-10}. The late region encodes the capsid proteins VP1 and VP2¹¹⁻¹³. LT and sT are the best-studied MCPyV proteins and have been shown to support the viral DNA replication and MCPyV-induced tumorigenesis⁵. Clonal integration of MCPyV DNA into the host genome, which has been observed in up to 80% of MCCs, is likely a causal factor for virus-positive tumor development^{14,15}.

The incidence of MCC has tripled over the past twenty years¹⁶. Asymptomatic MCPyV infection is also widespread in the general population¹⁷⁻¹⁹. With the increasing number of MCC diagnoses and the high prevalence of MCPyV infection, there is a need to improve our understanding of the virus and its oncogenic potential. However, many aspects of MCPyV biology and oncogenic mechanisms remain poorly understood²⁰. This is largely because MCPyV replicates poorly in established cell lines^{11,12,21-23} and, until recently, skin cells capable of supporting MCPyV infection had not been discovered²². Mechanistic studies to fully investigate MCPyV and its interaction with host cells have been hampered by a lack of cell culture system for propagating the virus⁵.

We discovered that primary human dermal fibroblasts (HDFs) isolated from neonatal human foreskin support robust MCPyV infection both *in vitro* and *ex vivo*²⁴. From this study, we established the first cell culture infection model for MCPyV²⁴. Building on this model system, we showed that the induction of matrix metalloproteinase (MMP) genes by the WNT/ β -catenin signaling pathway and other growth factors stimulates MCPyV infection. Moreover, we found that the FDA-approved MEK antagonist trametinib effectively inhibits MCPyV infection^{5,25}. From these studies, we also established a set of protocols for isolating human dermal fibroblasts^{24,25}, preparing MCPyV virions^{11,12}, performing MCPyV infection on human dermal fibroblasts^{24,25} and detecting MCPyV proteins by IF staining²⁶. In addition, we adapted the *in situ* DNA hybridization chain reaction (HCR) technology²⁷ to develop a highly sensitive FISH technique (HCR-DNA FISH) for detecting MCPyV DNA in infected human skin cells. These new methods will be useful for studying the infectious cycle of MCPyV as well as the cellular response to MCPyV infection. The natural host reservoir cells that maintain MCPyV infection and the cells that give rise to MCC tumors remain unknown. The techniques we describe in this manuscript could be applied to examine various types of human cells to identify both the reservoir cells and origin of MCC tumors. Our established methods, such as HCR-DNA FISH, could also be employed in the detection of other DNA tumor viruses and the characterization of host cell interactions.

PROTOCOL:

Human neonatal foreskins were obtained from Penn Skin Disease Research Center. Adult human

fibroblasts were obtained from discarded normal skin after surgery. All the protocols were approved by the University of Pennsylvania Institutional Review Board.

1. Isolation of human dermal fibroblasts

1.1) Use a pair of scissors to trim off fat and subcutaneous tissue from the human neonatal foreskin and cut the skin sample in halves or quarters.

1.2) Incubate the tissue in 5 mL of 10 mg/mL dispase II in PBS supplemented with antibiotic-antimycotic at 4 °C overnight.

1.3) In a sterile 10 cm dish, carefully separate the epidermis from the dermal layers using microdissection forceps.

1.4) Transfer the resulting dermal tissue to a 15 mL conical tube containing 5 mL of 2 mg/mL collagenase type IV in FBS-free medium supplemented with antibiotic-antimycotic.

1.5) Incubate the sample at 37 °C in 5% CO₂ for 4-6 h with periodic shaking until few macroscopic tissue aggregates are visible.

1.6) Release single cells from the dermis by pipetting up and down (trituration) vigorously ten times with a 10 mL pipette.

1.7) Centrifuge at 180 x *g* for 5 min, and discard the supernatant.

1.8) Plate the dissociated cells in DMEM medium supplemented with 10% fetal calf serum, 1% non-essential amino acids, and 1% L-glutamine at 37 °C in 5% CO₂.

2. Recombinant MCPyV virion preparation

2.1) Digest 50 µg of pR17b plasmid (carrying MCPyV genome) with 250 U of BamHI-HF in a 200 µL volume (4 h at 37 °C) to separate the viral genome from the vector backbone (**Figure 2**).

2.2) Add 1200 µL of buffer PB (supplemented with 10 µL of 3 M NaAc, pH 5.2) to the digested DNA and purify over 2 miniprep spin columns (20 µg DNA capacity). Elute the digested pR17b plasmid from each column with 200 µL of TE buffer (10 mM Tris-HCl, pH8.0, 1 mM EDTA).

2.3) Prepare the ligation reaction in a 50 mL centrifuge tube. Add 400 µL of purified plasmid DNA from step 2.2, 8.6 mL of 1.05x T4 ligase buffer and 6 µL of high concentration T4 ligase. Incubate at 16 °C overnight.

2.4) Add 45 mL of buffer PB (supplemented with 10 µL of 3 M NaAc, pH 5.2) to the ligation and use a vacuum manifold to load through 2 miniprep spin columns. Elute each column with 50 µL of TE buffer. Expect a yield of about 30 µg of DNA.

2.5) In the late afternoon/evening, seed 6×10^6 293TT²⁸ cells into a 10 cm dish containing DMEM medium supplemented with 10% fetal calf serum, 1% non-essential amino acids, and 1% L-glutamine without hygromycin B.

2.6) The next morning, ensure that the cells are about 50% confluent. Transfect using 66 μ L of transfection reagent ($1.1 \mu\text{L}/\text{cm}^2$), 12 μ g of re-ligated MCPyV isolate R17b DNA from step 2.4, 8.4 μ g of ST expression plasmid pMtB and 9.6 μ g of LT expression plasmid pADL*²⁹.

2.7) When the transfected cells are nearly confluent, the following day, trypsinize the cells and transfer them to a 15 cm dish for continued expansion.

2.8) Optionally take a small number of 293TT cells upon expansion and perform IF staining for MCPyV LT (CM2B4) and VP1 (MCV VP1 rabbit³⁰) to determine transfection efficiency. At this stage, nuclear LT signal may be visible but VP1 expression probably will not be detectable.

2.9) When the 15 cm dish becomes nearly confluent (usually 5-6 days after initial transfection), transfer the cells into three 15 cm dishes. Harvest the cells from the 15 cm dishes when they become nearly confluent and follow the virus harvest protocol below.

NOTE: Optionally perform quality control IF as described in step 2.8. Most of the cells should be both MCPyV LT and VP1 positive at this stage.

2.10) To harvest the virus, trypsinize cells, spin at $180 \times g$ for 5 min at RT and remove the supernatant. Add one cell pellet volume of DPBS-Mg (DPBS with 9.5 mM MgCl_2 and 1x antibiotic-antimycotic). Then add 25 mM ammonium sulfate (from a 1 M pH 9 stock solution) followed by 0.5% Triton X-100 (from a 10% stock solution), 0.1% Benzonase and 0.1% of an ATP-Dependent DNase. Mix well and incubate at 37 °C overnight.

2.11) Incubate the mixture for 15 min on ice and then add 0.17 volume of 5M NaCl. Mix and incubate on ice for another 15 min. Spin for 10 min at $12,000 \times g$ in a 4 °C centrifuge. If the supernatant is not clear, gently invert the tube and repeat the spinning step. Transfer the supernatant to a new tube.

2.12) Resuspend the pellet using one volume of DPBS supplemented with 0.8 M NaCl, and spin again, as described in step 2.11.

2.13) Combine the supernatants from the step 2.11 and 2.12, and spin one more time as described in step 2.11.

2.14) Pour gradients of iodixanol in thin wall 5 mL polyallomer tubes by underlaying (27%, then 33%, then 39%) ~0.7 mL steps using a 3 mL syringe fitted with a long needle or a p1000 pipette.

2.15) Load 3 mL of clarified virus-containing supernatant on the prepared iodixanol gradient.

2.16) Spin for 3.5 h at 234,000 x *g* and 16 °C in an SW55ti rotor. Set the acceleration and deceleration to slow.

2.17) After ultracentrifugation, collect 12 fractions in siliconized tubes (each fraction is ~400 µL).

2.18) Analyze the fractions for the presence of virus by dsDNA reagent and/or Western blot for VP1 (MCV VP1 rabbit³⁰). Pool gradient fractions with peak dsDNA and/or VP1 content and characterize the stock by quantitative PCR to calculate the viral genome equivalent³¹. Store MCPyV virion stock at -80 °C.

3. Infection

3.1) Maintain primary human dermal fibroblasts in DMEM with 10% fetal calf serum, 1% non-essential amino acids and 1% L-glutamine. Upon reaching confluence, split fibroblasts 1:4 without spinning down.

NOTE: For highest MCPyV infection efficiency, use primary fibroblasts between passages 5 and 12 that are actively dividing at the time of plating.

3.2) To infect human dermal fibroblasts, aspirate the medium and wash the cells with DPBS.

3.3) Add 1 mL of 0.05% Trypsin-EDTA to the dish and incubate at 37 °C for 5-10 min.

3.4) Check under the microscope to make sure that the cells are coming off the dish.

3.5) Add 10 mL of DMEM/F12 medium containing 20 ng/mL EGF, 20 ng/mL bFGF and 3 µM CHIR99021, all of which stimulate MCPyV infection²⁴, to the dish and transfer the cell solution into a 15 mL tube.

3.6) Spin down the cells at 180 x *g* for 2 min, and discard the supernatant. Resuspend the cells in DMEM/F12 medium containing 20 ng/mL EGF, 20 ng/mL bFGF and 3µM CHIR99021 at 2-4 x 10⁴ cells per mL.

3.7) Seed 200 µL of the cell suspension supplemented with 1 mg/mL collagenase type IV into each well of a 96-well plate. Thaw MCPyV virion stock on ice. Add 10⁹ viral genome equivalents of MCPyV virions (calculated in step 2.18) in 1 µL volumes to the cells. Tap the side of the plate gently and place the plate in the incubator.

3.8) After incubation at 37 °C in 5% CO₂ for 48-72 h, add 20% FBS to each well.

3.9) Allow the infection to proceed at 37 °C in 5% CO₂ for 72-96 h.

4. Immunofluorescent staining

4.1) Fix cells obtained in step 3.9 with 3% paraformaldehyde in PBS for 20 min.

4.2) Wash the cells with PBS twice.

4.3) Incubate the cells in blocking/permeabilization buffer (0.5% Triton X-100, 3% BSA in PBS filtered through 0.22 µm filter) at RT for 1 h.

4.4) Incubate the cells with the following primary antibodies: mouse monoclonal anti-MCPyV LT (CM2B4) (1:1000) and rabbit polyclonal anti-MCPyV VP1 antibody (1:2000), at RT for 3 h.

4.5) Wash the cells with PBS three times.

4.6) Incubate the cells with the secondary antibodies: Fluor 594 goat anti-mouse IgG (1:1000) and Fluor 488 goat anti-rabbit IgG (1:500) at RT for 1 h.

4.7) Wash cells with PBS three times.

4.8) Counterstain the cells with 0.5 µg/mL DAPI (4',6-Diamidino-2-Phenylindole, Dihydrochloride).

4.9) Mount coverslips on glass slides and analyze using an inverted fluorescence microscope.

5. In situ DNA-HCR

NOTE: This technique requires that cells be seeded on coverslips. For this purpose, the infection conditions described above (step 3) may be scaled up to the 24-well plate format.

5.1) Fix cells cultured on coverslips with 4% PFA in PBS for 10 min. Wash the coverslips twice with PBS, then treat them with 70% ethanol to permeabilize the cells at 4 °C overnight.

NOTE: Fixed samples can remain in this state for several days.

5.2) Pre-hybridize samples by replacing the ethanol with probe hybridization buffer and incubating for 60 min at RT.

5.3) Dilute the probe(s) (1 µM) (Table 1) in probe hybridization buffer solution at 1:500 dilution 30 min prior to the end of the pre-hybridization step and incubate at 45 °C.

5.4) At the end of the incubations, pipette ~10 µL of the diluted probe mix per coverslip on microscope slides. Place the coverslips, cell-side down, on their respective droplets of hybridization probe mix. Seal the edges and backs of the coverslips to the slides with a liberal amount of rubber cement.

5.5) Heat the slides with added probes at 94 °C for 3 min by setting the slides on the flat side of a heat block. Transfer the slides to a humidified chamber and incubate at 45 °C overnight. To make a simple humidified chamber, lightly dampen sterile paper towels with dH₂O and place in the bottom of a plastic container that seals with a rubber gasket.

NOTE: During heating the rubber cement can bubble briefly. However, ensure that the seal does not break.

5.6) Carefully peel away the rubber cement with forceps and place the coverslips cell-side up back into wells of a 24-well plate. Wash the coverslips with probe wash buffer at RT three times.

5.7) Incubate the coverslip in the amplification buffer (200 µL in 24-well plates) at RT 30-60 min.

5.8) Meanwhile, anneal each of the two labeled oligonucleotide hairpins recognizing the probes (**Table 1**) in separate PCR tubes by heating to 95 °C for 90 s and cooling to RT for 30 min while protecting from light. Mix the two hairpins in amplification buffer, each at a dilution of 1:50.

5.9) Make a surface for the amplification reaction by stretching paraffin film over the open face of a 24-well plate lid. Pipette 50-100 µL droplets of the hairpin/amplification buffer mixture onto the paraffin film for each coverslip. Use forceps to carefully remove the coverslips from the pre-amplification solution. Dry the coverslip by touching the edge to a porous disposable wipe, and place cell-side down onto the amplification droplet.

5.10) Place the plate lid holding the coverslips into a humidified chamber and incubate overnight at RT in the dark.

5.11) Return the coverslips to wells once more. Incubate the samples with 5x SSCT [5x sodium chloride sodium citrate (SSC) 0.1% Tween 20 filtered through a 0.22 µm filter] containing 0.5 µg/mL DAPI for 1 h at RT. Wash the samples twice with 5x SSCT at RT.

5.12) Mount the coverslips on microscope slides. Analyze the cells and image the samples using an inverted fluorescence microscope.

REPRESENTATIVE RESULTS:

The protocol described in this manuscript allowed isolation of a nearly homogenous population of HDFs (**Figure 1**). As demonstrated by immunofluorescent staining, almost 100% of the human dermal cells isolated using the conditions described in this protocol were positively stained for dermal fibroblast markers, vimentin, and collagen I²⁴, but negative for human foreskin keratinocyte marker K14 (**Figure 1**). **Figure 2** shows the process of generating MCPyV virions using recombinant MCPyV genome and a virion sample after ultracentrifuge concentration. After visualizing the band of MCPyV virions concentrated in the core of the gradient (marked by an

arrow in **Figure 2B**), 500 μ L fractions were collected and MCPyV qPCR was performed to identify the peak fractions. An example of the qPCR analysis data is shown in **Figure 2C**. In some other experiments, the samples were also analyzed with Western blotting using a rabbit-anti-MCPyV VLP antibody (**Supplemental Figure 1**). **Figure 3** shows immunofluorescent stained images of HDFs infected with MCPyV. To manually quantify positive cells, we counted at least three random views of about 300 cells. We consider cells that are LT positive, VP1 positive, or both LT and VP1 positive to be positive for MCPyV infection. In the experiments shown in **Figure 3**, over 30% of cells are LT positive and more than 10% are VP1 positive. The MCPyV genomes replicated in the infected cells were detected using both the HCR-DNA FISH (**Figure 4A**) and Immunofluorescent-HCR-DNA FISH (**Figure 4B**). While the HCR-DNA FISH reveals the localization of MCPyV DNA present in the replication factory (foci) in **Figure 4A**, the Immunofluorescent-HCR-DNA FISH methods allows simultaneous detection of both MCPyV DNA and LT protein co-localizing at the replication centers (**Figure 4B**). The images from the immunofluorescent-HCR-DNA FISH demonstrated that this technique could be used to reveal co-localization of viral DNA and the associated viral protein.

FIGURE AND TABLE LEGENDS:

Figure 1. Human dermal fibroblasts isolated from neonatal human foreskin. Human dermal cells cultured in DMEM/F12 medium supplemented with 10% FBS were stained using antibodies against vimentin, collagen I, or keratin 14 (K14). The cells were also counterstained with DAPI. Bar, 50 μ m. This figure was adapted from **Figure S2 of Liu et al., 2016²⁴**.

Figure 2. Production of MCPyV virion using recombinant viral genome. (A) A plasmid map of pR17b (MCPyV genome plasmid). (B) A representative picture of an MCPyV virion sample harvested and purified over a gradient. Arrow marks the band of MCPyV virions concentrated in the core of the gradient. (C) The viral genome copy number in each gradient fraction was quantified using qPCR. Core gradient fractions (numbers, counting from the top of the gradient, are indicated at the bottom of the graph). Error bars represent standard error of the mean (S.E.M.) of three technical repeats.

Figure 3. Human dermal fibroblasts support robust MCPyV infection, transcription, and replication. Dermal fibroblasts isolated from human skin were treated with MCPyV virions in DMEM F12 medium containing EGF, bFGF, CHIR99021, and collagenase IV for two days. After changing to fresh DMEM/F12 medium containing 20% FBS for three more days, cells were immuno-stained using the indicated antibodies and counterstained with DAPI. Many of cells not only have highly expressed LT and VP1 but also show robust MCPyV replication foci. This figure was adapted from Figure 3 of Liu et al., 2016²⁴. Scale bar, 50 μ m.

Figure 4. Detection of MCPyV in infected cells using FISH techniques. (A) Human dermal cells cultured in DMEM/F12 containing EGF, bFGF, CHIR99021, and collagenase type IV were treated with MCPyV for 2 days. After changing to fresh DMEM/F12 containing FBS for 3 more days, the cells were subjected to HCR-DNA FISH analysis. The cells were also counterstained with DAPI. (B) Human dermal cells cultured in medium containing EGF, bFGF, and CHIR99021 were either

untreated (Mock) or treated (Infected) with MCPyV as described in (A). The cells were subjected to immuno-FISH using LT antibody and MCPyV-specific DNA probes before counterstaining with DAPI. HPV16 probes were used as a negative control. Scale bar, 10 μ m. This figure was adapted from Figure 4 of Liu et al., 2016²⁴.

Table 1: Probes used in the study.

Supplemental Figure 1. Screening Iodixanol gradient fractions for MCPyV VP1. MCPyV-infected cells were lysed and subjected to Iodixanol gradient fractionation. Core gradient fractions (numbers, counting from the bottom of the gradient in this experiment, are indicated at the top of the figure) were subjected to Western blot analysis to detect VP1. 10 μ L samples of each fraction were adjusted to 1x load dye with a 5% final concentration of 2-mercaptoethanol and briefly heated to 65 °C. The samples were separated on a 4-12% bis-Tris gel and blotted onto nitrocellulose. Western blotting was conducted in TBST with nonfat dry milk using a rabbit-anti-MCPyV VLP antiserum diluted 1:5000. The antiserum is available upon request. The 50 kDa standard (which migrates similarly to the 47 kDa MCPyV VP1 monomer) is marked with an asterisk. In the shown image, sample reduction was incomplete and disulfide-linked VP1 multimers are apparent. Use of dithiothreitol and/or higher denaturation temperatures can result in more complete reduction to the VP1 monomer species.

DISCUSSION:

The methods described above, including isolation of dermal fibroblasts from human skin tissue, preparation of recombinant MCPyV virions, infection of cultured cells, immunofluorescent staining, and a sensitive FISH method adapted from HCR technology, which should enable researchers to analyze MCPyV infection²⁷. One of the most critical steps to achieving MCPyV infection in vitro is the production of high-titer virion preparations. Using the protocol for preparation of recombinant MCPyV virions described here, we achieve viral titers of 10^{12} genome copies per mL of iodixanol solvent^{11,12}. These high-titer MCPyV preparations allowed us to identify HDFs as the only primary skin cell type thus far that appears to support the full MCPyV infection cycle²⁴.

Isolating fresh human dermal fibroblasts using the protocol described in this manuscript has enabled us to control the quality of the cells used in MCPyV infection experiment and ensure consistency of findings across cells isolated from different patient samples. All human dermal fibroblasts isolated from neonatal skin should be assessed for presence of MCPyV DNA by qPCR to ensure the absence of MCPyV infection prior to treatment with recombinant MCPyV virions. In order to obtain the maximum MCPyV infection efficiency, it is critical to use human dermal fibroblasts isolated freshly from neonatal human foreskin as higher passage fibroblasts support lower MCPyV infection efficiencies. Further, when isolated in parallel from adult skin samples, fibroblasts from neonatal skin samples supported much higher MCPyV infection efficiency²⁴. We have never tested any commercially available cells for MCPyV infection. However, we see no specific reason that commercially isolated fibroblasts should be inferior other than if they are higher passage at the point of freezing.

We have also used the protocol described here to isolate dermal fibroblasts from other animals. For example, we have used the protocol to successfully isolate dermal fibroblasts from mouse (*Mus musculus*), rat (*Rattus norvegicus*), tree shrew (*Tupaia Belangeri*), and rhesus macaque (*Macaca mulatta*)²⁵. As observed in human cells, fibroblasts isolated from younger chimpanzees allowed much more efficient MCPyV infection compared to the older animals²⁵.

Compared to traditional FISH, HCR-DNA FISH is a simple, but highly sensitive method for detecting viral genomes^{24,27}. Centers of MCPyV replication can be readily detected in the nuclei of infected cells as highly specific punctate foci, with little to no background signal detected in the same samples treated with a HPV specific probe (**Figure 4**)²⁴. In the future, the approach could therefore be explored to detect low-abundance MCPyV DNA present in infected human skin. It could also be adapted to monitor other DNA viruses. When combined with immunofluorescent staining, the immuno-FISH provides a powerful method for simultaneously detecting viral DNA and either viral encoded protein or host proteins present in the same cells (**Figure 4**). For obtaining the optimum results using the protocols described here, it is best to use freshly fixed samples for immunofluorescent staining and HCR-DNA FISH analysis. For the HCR-DNA FISH analysis, the probes and amplifier should be stored in -80 °C in small aliquots to avoid repeated freezing and thawing.

Using the HDF cell culture and MCPyV infection protocol, we explored the cell growth conditions that best support MCPyV entry, transcription, and replication in HDFs. We discovered that treatment of HDFs with growth factors, such as EGF, bFGF, and stimulation of the WNT signaling pathway significantly promote MCPyV infection. Gene expression profiling reveals that, upon stimulation with these growth factors and activation of the WNT signaling pathway, several genes of the matrix metalloproteinase (MMP) family, including MMP1, 3, 7, 9, 10, 11 and 13, were robustly induced. Because these MMP enzymes are capable of degrading extracellular matrix proteins, we reason that they may stimulate MCPyV infection by disrupting the extracellular matrix of the host cells. Indeed, treating HDFs with collagenase type IV, a member of the MMP family, robustly stimulates MCPyV infection (**Figure 3**)²⁴. We also screened an array of compounds, including several FDA-approved kinase inhibitors, for inhibitory effect on MCPyV infection. We discovered that trametinib, a MEK1 and MEK2 inhibitor, dramatically inhibits MCPyV infection²⁴. Others may use or modify this infection system as a drug discovery platform for MCPyV inhibitors that reduce the MCPyV viral load in immunocompromised patients.

In summary, these protocols for achieving highly efficient MCPyV infection provide a platform to elucidate the poorly understood MCPyV infectious cycle and MCPyV-induced oncogenic mechanisms in the context of viral infection. This set of protocols could be applied in future studies to explore additional MCPyV-permissive human cell types, and the original cells of MCC, in which incidental MCPyV infection could lead to tumor development.

ACKNOWLEDGMENTS:

The authors would like to thank Dr. Meenhard Herlyn (Wistar Institute) and Dr. M. Celeste Simon (University of Pennsylvania) for providing reagents and technical support. We also thank the members of our laboratories for helpful discussion. This work was supported by the National

Institutes of Health (NIH) grants (R01CA187718, R01CA148768 and R01CA142723), the NCI Cancer Center Support Grant (NCI P30 CA016520), and the Penn CFAR award (P30 AI 045008).

DISCLOSURES:

The authors have nothing to disclose.

REFERENCES:

- 1 Gjoerup, O., Chang, Y. in *Advances in Cancer Research* Vol. Volume 106 eds F. Vande Woude George & Klein George) 1-51 (Academic Press, 2010).
- 2 Feng, H., Shuda, M., Chang, Y. & Moore, P. S. Clonal integration of a polyomavirus in human Merkel cell carcinoma. *Science*. **319** (5866), 1096-1100, 10.1126/science.1152586 (2008).
- 3 Lemos, B., Nghiem, P. Merkel cell carcinoma: more deaths but still no pathway to blame. *Journal of Investigative Dermatology*. **127** (9), 2100-2103, 10.1038/sj.jid.5700925 (2007).
- 4 Agelli, M., Clegg, L. X. Epidemiology of primary Merkel cell carcinoma in the United States. *Journal of the American Academy of Dermatology*. **49** (5), 832-841 (2003).
- 5 Liu, W., MacDonald, M., You, J. Merkel cell polyomavirus infection and Merkel cell carcinoma. *Current Opinion in Virology*. **20** 20-27, 10.1016/j.coviro.2016.07.011 (2016).
- 6 Harrison, C. J. et al. Asymmetric Assembly of Merkel Cell Polyomavirus Large T-Antigen Origin Binding Domains at the Viral Origin. *Journal of Molecular Biology*. **409** (4), 529-542, [10.1016/j.jmb.2011.03.051](https://doi.org/10.1016/j.jmb.2011.03.051) (2011).
- 7 Kwun, H. J. et al. The Minimum Replication Origin of Merkel Cell Polyomavirus Has a Unique Large T-Antigen Loading Architecture and Requires Small T-Antigen Expression for Optimal Replication. *Journal of Virology*. **83** (23), 12118-12128, 10.1128/jvi.01336-09 (2009).
- 8 Carter, J. J. et al. Identification of an overprinting gene in Merkel cell polyomavirus provides evolutionary insight into the birth of viral genes. *Proceedings of the National Academy of Sciences of the United States of America*. **110** (31), 12744-12749, 10.1073/pnas.1303526110 (2013).
- 9 Seo, G. J., Chen, C. J., Sullivan, C. S. Merkel cell polyomavirus encodes a microRNA with the ability to autoregulate viral gene expression. *Virology*. **383** (2), 183-187, 10.1016/j.virol.2008.11.001 (2009).
- 10 Theiss, J. M. et al. A Comprehensive Analysis of Replicating Merkel Cell Polyomavirus Genomes Delineates the Viral Transcription Program and Suggests a Role for mcv-miR-M1 in Episomal Persistence. *PLOS Pathogens*. **11** (7), e1004974, 10.1371/journal.ppat.1004974 (2015).
- 11 Schowalter, R. M., Pastrana, D. V., Buck, C. B. Glycosaminoglycans and sialylated glycans sequentially facilitate Merkel cell polyomavirus infectious entry. *PLOS Pathogens*. **7** (7), e1002161, 10.1371/journal.ppat.1002161 (2011).
- 12 Schowalter, R. M., Reinhold, W. C., Buck, C. B. Entry Tropism of BK and Merkel Cell Polyomaviruses in Cell Culture. *PLoS One*. **7** (7), e42181, 10.1371/journal.pone.0042181 (2012).
- 13 Schowalter, R. M., Buck, C. B. The Merkel cell polyomavirus minor capsid protein. *PLOS Pathogens*. **9** (8), e1003558, 10.1371/journal.ppat.1003558 (2013).

485 14 Houben, R., Schrama, D., Becker, J. C. Molecular pathogenesis of Merkel cell carcinoma.
486 *Experimental Dermatology*. **18** (3), 193-198, 10.1111/j.1600-0625.2009.00853.x (2009).

487 15 Chang, Y., Moore, P. S. Merkel cell carcinoma: a virus-induced human cancer. *Annual*
488 *Review of Pathology*. **7** 123-144, 10.1146/annurev-pathol-011110-130227 (2012).

489 16 Hodgson, N. C. Merkel cell carcinoma: Changing incidence trends. *Journal of Surgical*
490 *Oncology*. **89** (1), 1-4, 10.1002/jso.20167 (2005).

491 17 Tolstov, Y. L. et al. Human Merkel cell polyomavirus infection II. MCV is a common human
492 infection that can be detected by conformational capsid epitope immunoassays.
493 *International Journal of Cancer*. **125** (6), 1250-1256, 10.1002/ijc.24509 (2009).

494 18 Schowalter, R. M., Pastrana, D. V., Pumphrey, K. A., Moyer, A. L., Buck, C. B. Merkel cell
495 polyomavirus and two previously unknown polyomaviruses are chronically shed from
496 human skin. *Cell Host & Microbe*. **7** (6), 509-515, 10.1016/j.chom.2010.05.006 (2010).

497 19 Foulongne, V. et al. Human Skin Microbiota: High Diversity of DNA Viruses Identified on
498 the Human Skin by High Throughput Sequencing. *PLoS One*. **7** (6), e38499,
499 10.1371/journal.pone.0038499 (2012).

500 20 Hopcraft, S. E., Damania, B. Tumour viruses and innate immunity. *Philosophical*
501 *Transactions of the Royal Society of London. Series B, Biological Sciences*.. **372** (1732),
502 10.1098/rstb.2016.0267 (2017).

503 21 Feng, H. et al. Cellular and viral factors regulating Merkel cell polyomavirus replication.
504 *PLoS One*. **6** (7), e22468, 10.1371/journal.pone.0022468 (2011).

505 22 Neumann, F. et al. Replication, Gene Expression and Particle Production by a Consensus
506 Merkel Cell Polyomavirus (MCPyV) Genome. *PLoS One*. **6** (12), e29112,
507 10.1371/journal.pone.0029112 (2011).

508 23 Tsang, S. H., Wang, X., Li, J., Buck, C. B., You, J. Host DNA damage response factors localize
509 to merkel cell polyomavirus DNA replication sites to support efficient viral DNA
510 replication. *Journal of Virology*. **88** (6), 3285-3297, 10.1128/jvi.03656-13 (2014).

511 24 Liu, W. et al. Identifying the Target Cells and Mechanisms of Merkel Cell Polyomavirus
512 Infection. *Cell Host & Microbe*. **19** (6), 775-787, 10.1016/j.chom.2016.04.024 (2016).

513 25 Liu, W., Krump, N. A., MacDonald, M., You, J. Merkel Cell Polyomavirus Infection of Animal
514 Dermal Fibroblasts. *Journal of Virology*. **92** (4), 10.1128/jvi.01610-17 (2018).

515 26 Liu, W. et al. BRD4 regulates Nanog expression in mouse embryonic stem cells and
516 preimplantation embryos. *Cell Death Differ*. **21** (12), 1950-1960, 10.1038/cdd.2014.124
517 (2014).

518 27 Choi, H. M., Beck, V. A., Pierce, N. A. Next-generation in situ hybridization chain reaction:
519 higher gain, lower cost, greater durability. *ACS Nano*. **8** (5), 4284-4294,
520 10.1021/nn405717p (2014).

521 28 Buck, C. B., Pastrana, D. V., Lowy, D. R., Schiller, J. T. Efficient intracellular assembly of
522 papillomaviral vectors. *Journal of Virology*. **78** (2), 751-757 (2004).

523 29 <https://home.ccr.cancer.gov/lco/support.htm> (2018).

524 30 <https://home.ccr.cancer.gov/lco/BuckLabAntibodies.htm> (2018).

525 31 <https://home.ccr.cancer.gov/lco/NativeMCVproduction.htm> (2018).

526


Figure 1




Figure 2**A****B****C**




Figure 3

Figure 4**A****B**

Probe name	Sequences
MCPyV probe 1	CCTCAACCTACCTCCAACCTCTCACCATATTCGCTTC TAAAA tgagctacactcactaaggagtggtttttatactgcagtttcccgcccttg ATTTT CACATTTACAGACCTCAACCTACCTCCAACCTCTCAC
MCPyV probe 2	CCTCAACCTACCTCCAACCTCTCACCATATTCGCTTC TAAAA agaggcctcgaggctaggagcccaagcctctgccaactgaaaaaaa ATTTT CACATTTACAGACCTCAACCTACCTCCAACCTCTCAC
MCPyV probe 3	CCTCAACCTACCTCCAACCTCTCACCATATTCGCTTC TAAAA cattgactcatttcctggagaggcgagtttgactgataaacaacttt ATTTT CACATTTACAGACCTCAACCTACCTCCAACCTCTCAC
MCPyV probe 4	CCTCAACCTACCTCCAACCTCTCACCATATTCGCTTC TAAAA gatactgcctttttgctaattaagcctcttaagcctcagagtcctctct ATTTT CACATTTACAGACCTCAACCTACCTCCAACCTCTCAC
MCPyV probe 5	CCTCAACCTACCTCCAACCTCTCACCATATTCGCTTC TAAAA aagccttcctgtaagaatagcttccaaagttaactcctgtggtggcaatt ATTTT CACATTTACAGACCTCAACCTACCTCCAACCTCTCAC
MCPyV probe 6	CCTCAACCTACCTCCAACCTCTCACCATATTCGCTTC TAAAA ggatgttgccataacaattaggagcaatctccaaaagcctgcacagagcc ATTTT CACATTTACAGACCTCAACCTACCTCCAACCTCTCAC
MCPyV probe 7	CCTCAACCTACCTCCAACCTCTCACCATATTCGCTTC TAAAA gctcaggggaggaaagtgttcacgcagaagagatcctccaggtgcc ATTTT CACATTTACAGACCTCAACCTACCTCCAACCTCTCAC
MCPyV probe 8	CCTCAACCTACCTCCAACCTCTCACCATATTCGCTTC TAAAA aagcctgggacgctgagaaggaccataccagaggaagagctctggctg ATTTT CACATTTACAGACCTCAACCTACCTCCAACCTCTCAC
MCPyV probe 9	CCTCAACCTACCTCCAACCTCTCACCATATTCGCTTC TAAAA agcttcgggaccccccaattttcgctttcttgagaatggaggagggtc ATTTT CACATTTACAGACCTCAACCTACCTCCAACCTCTCAC
MCPyV probe 10	CCTCAACCTACCTCCAACCTCTCACCATATTCGCTTC TAAAA ctttggctagaacagtgtctgcggctgttgccaagtgtttctgaga ATTTT CACATTTACAGACCTCAACCTACCTCCAACCTCTCAC
HPV probe 1	CCTCAACCTACCTCCAACCTCTCACCATATTCGCTTC TAAAA cagctctgtgcataactgtggttaactttctgggtcgtcctgtgggtcct ATTTT CACATTTACAGACCTCAACCTACCTCCAACCTCTCAC
HPV probe 2	CCTCAACCTACCTCCAACCTCTCACCATATTCGCTTC TAAAA acaatattgtaatgggctctgtccggttctgctgtccagctggaccatc ATTTT CACATTTACAGACCTCAACCTACCTCCAACCTCTCAC
HPV probe 3	CCTCAACCTACCTCCAACCTCTCACCATATTCGCTTC TAAAA gtcagctatactgggtgtaagtccaatgcagcaatacaccaatcgcaac ATTTT CACATTTACAGACCTCAACCTACCTCCAACCTCTCAC
HPV probe 4	CCTCAACCTACCTCCAACCTCTCACCATATTCGCTTC TAAAA ctttggtatgggtcgcggcggtgttgccaagtgtgcctaataatt ATTTT CACATTTACAGACCTCAACCTACCTCCAACCTCTCAC
HPV probe 5	CCTCAACCTACCTCCAACCTCTCACCATATTCGCTTC TAAAA ccatccattacatcccgtaacctcttcccattgtacctgcaggatcag ATTTT CACATTTACAGACCTCAACCTACCTCCAACCTCTCAC

Name of Material/ Equipment	Company	Catalog Number	Comments/Description
Fetal calf serum	HyClone	SH30071.03	
MEM Non-Essential Amino Acids Solution, 100X	Thermo Fisher Scientific	11140050	
GLUTAMAX I, 100X	Thermo Fisher Scientific	35050061	L-Glutamine
DPBS, no calcium, no magnesium	Thermo Fisher Scientific	14190136	
0.05% Trypsin-EDTA	Thermo Fisher Scientific	25300-054	
DMEM/F12 medium	Thermo Fisher Scientific	11330-032	
Recombinant Human EGF Protein, CF	R&D systems	236-EG-200	Store at -80 degree celsius
CHIR99021	Cayman Chemical	13122	Store at -80 degree celsius
CHIR99021	Sigma	SML1046	Store at -80 degree celsius
Collagenase type IV	Thermo Fisher Scientific	17104019	
Dispase II	Roche	4942078001	
Antibiotic-Antimycotic	Thermo Fisher Scientific	15240-062	Protect from light
DMEM medium	Thermo Fisher Scientific	11965084	
Alexa Fluor 594 goat anti-mouse IgG	Thermo Fisher Scientific	A11032	Protect from light
Alexa Fluor 488 goat anti-rabbit IgG	Thermo Fisher Scientific	A11034	Protect from light
OptiPrep Density Gradient Medium	Sigma	D1556	Protect from light
Paraformaldehyde	Sigma	P6148	
anti-MCPyV LT (CM2B4)	Santa Cruz	sc-136172	Lot # B2717
MCV VP1 rabbit		Rabbit polyclonal s	https://home.ccr.cancer.gov/lco/BuckLabAntibodies.htm
Hygromycin	Roche	10843555001	
Basic Fibroblast Growth Factors (bFGF), Human			
Recombinant	Corning	354060	Store at -80 degree celsius
Benzonase Nuclease	Sigma	E8263	
Plasmid-Safe ATP-Dependent DNase	EPICENTRE	E3101K	
Probe hybridization buffer	Molecular technologies		
Probe wash buffer	Molecular technologies		
Amplification buffer	Molecular technologies		
Alexa 594-labeled hairpins	Molecular technologies	B4	Protect from light
Triton X-100	Sigma	X100	
Quant-iT PicoGreen dsDNA Reagent	Thermo Fisher Scientific	P7581	
BamHI-HF	NEB	R3136	
Buffer PB	Qiagen	19066	
blue miniprep spin column	Qiagen	27104	
50mL Conical Centrifuge Tubes	Corning	352070	
T4 ligase	NEB	M0202T	
MagicMark XP	Thermo Fisher Scientific	LC5602	



1 Alewife Center #200
Cambridge, MA 02140
tel. 617.945.9051
www.jove.com

ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article:	A cell culture model for Merkel cell polyomavirus infection
Author(s):	Wei Liu*, Nathan Krump*, Christopher B. Buck, and Jianxin You#

Item 1: The Author elects to have the Materials be made available (as described at <http://www.jove.com/publish>) via:



Standard Access



Open Access

Item 2: Please select one of the following items:



The Author is **NOT** a United States government employee. except Christopher B. Buck



The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.



The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: **"Agreement"** means this Article and Video License Agreement; **"Article"** means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; **"Author"** means the author who is a signatory to this Agreement; **"Collective Work"** means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; **"CRC License"** means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; **"Derivative Work"** means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; **"Institution"** means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; **"JoVE"** means MyJoVE Corporation, a Massachusetts corporation and the publisher of The Journal of Visualized Experiments; **"Materials"** means the Article and / or the Video; **"Parties"** means the Author and JoVE; **"Video"** means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion

of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to **Sections 4** and **7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the "Open Access" box has been checked in **Item 1** above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

ARTICLE AND VIDEO LICENSE AGREEMENT

4. **Retention of Rights in Article.** Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. **Grant of Rights in Video – Standard Access.** This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. **Grant of Rights in Video – Open Access.** This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this **Section 6** is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. **Government Employees.** If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum

rights permitted under such statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. **Protection of the Work.** The Author(s) authorize JoVE to take steps in the Author(s) name and on their behalf if JoVE believes some third party could be infringing or might infringe the copyright of either the Author's Article and/or Video.

9. **Likeness, Privacy, Personality.** The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

10. **Author Warranties.** The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

11. **JoVE Discretion.** If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole

ARTICLE AND VIDEO LICENSE AGREEMENT

discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

12. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to


the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

13. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

14. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement is required per submission.

CORRESPONDING AUTHOR

Name:	Jianxin You, PhD		
Department:	Microbiology		
Institution:	University of Pennsylvania Perelman School of Medicine		
Title:	Associate Professor		
Signature:		Date:	Aug 3, 2018

Please submit a **signed** and **dated** copy of this license by one of the following three methods:

1. Upload an electronic version on the JoVE submission site
2. Fax the document to +1.866.381.2236
3. Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02140



Jianxin You, Ph.D.
Associate Professor, Department of Microbiology

Department of Microbiology

Oct 25, 2018

Editors

JoVE

Dear Dr. Vineeta Bajaj:

Thank you very much for spending the time reviewing our manuscript. Enclosed please find a copy of our revised manuscript (JoVE58950R1). We have carefully addressed all of the comments from you and tracked the changes made to the manuscript. For some of the editorial comments that need further response or clarification, we have added **Author Responses** within individual editorial comment sections of the manuscript.


We hope that you find the revised manuscript now acceptable for publication in **JoVE**. Thank you very much for your attention.

Sincerely,

Jianxin You

Jianxin You, Ph.D.
Department of Microbiology
University of Pennsylvania Perelman School of Medicine

Supplemental Figure 1



Copyright permission

We have adapted figures from our previous papers published in Cell Host & Microbe and JVI. Both Journals give their authors permission to reuse published figures as long as we cite the original publication. These editorial policies can be found at the following links:

Cell Host & Microbe:

<https://www.cell.com/cell-host-microbe/authors>

JVI:

<https://journals.asm.org/content/statement-author-rights>